Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma

Nature Clinical Practice Nephrology

Volumn 3, Issue 5, 2007, Pages 287-293

  Roncone, Daniel ^a   Satoskar, Anjali ^a   Nadasdy, Tibor ^a   Monk, J Paul ^a   Rovin, Brad H ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Anti VEGF therapy; Endothelial injury; Proteinuria; Renal cell carcinoma; Thrombotic microangiopathy

Indexed keywords

ALPHA2B INTERFERON; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BEVACIZUMAB; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN A; LISINOPRIL; QUINAPRIL; TELMISARTAN; VASCULOTROPIN ANTIBODY;

ADULT; ANXIETY; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE REGULATION; CASE REPORT; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GLOMERULUS CAPILLARY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNE COMPLEX NEPHRITIS; KIDNEY BIOPSY; KIDNEY CARCINOMA; MALE; MESANGIUM; METASTASIS; MICROANGIOPATHY; NEPHRECTOMY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; THROMBOSIS; URINALYSIS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; HUMANS; INTERFERON ALFA-2B; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEINURIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247597779     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0476     Document Type: Article

References (18)

1. 1 murine systemic lupus erythematosus model. Clin Can Res 11: 407-409
2. Rini BI and Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Onc 23: 1028-1043
3. Gordon MS and Cunningham D (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69 (Suppl 3): S25-S33
4. Rini BI et al. (2004) Cancer and leukemia group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Can Res 10: 2584-2586
5. Yang JC et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Eng J Med 349: 427-434
6. Ellis LM et al. (2006) Overview of anti-VEGF therapy and angiogenesis: angiogenesis inhibition in solid tumor malignancies. Clin Adv Hematol Oncol 4 (Suppl 1): S1-S12
7. Jain RK et al. (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40
8. Schrijvers BF et al. (2004) The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65: 2003-2017
9. Badid C et al. (2001) Renal thrombotic microangiopathy induced by interferon-alpha. Nephrol Dial Transplant 16: 846-848
10. De Vriese AS et al. (2001) Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12: 993-1000
11. Gordon A et al. (2004) Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy. Nephrol Dial Transplant 19: 2155-2157
12. Sugimoto H et al. (2003) Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278: 12605-12608
13. Eremina V et al. (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707-716
14. Maynard SE et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658
15. Karumanchi SA et al. (2005) Preeclampsia: a renal perspective. Kidney Int 67: 2101-2113
16. Shimizu A et al. (2004) Vascular endothelial growth factor-165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol 15: 2655-2665
17. Masuda Y et al. (2001) Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 159: 599-608
18. Ha SI et al. (2002) Glucocorticoid diminishes vascular endothelial growth factor and exacerbates proteinuria in rats with mesangial proliferative glomerulonephritis. Am J Kidney Dis 39: 1001-1010